R21/Matrix-M booster maintains high efficacy against first and multiple episodes of clinical malaria
The phase 1/2b clinical trial on R21/Matrix-M malaria vaccine has recently reported the safety and efficacy of booster vaccination at 12 months. The entire report has been published in The Lancet ...
The R21/Matrix-M™ malaria vaccine is one step closer to mass rollout, after officially receiving WHO prequalification status, making it eligible for procurement by United Nations agencies. • ...
(RTTNews) - Novavax, Inc. (NVAX) announced Tuesday progress on its collaboration and license agreement (CLA) with Sanofi SA (SNY) regarding Novavax's Matrix-M adjuvant. The companies have amended ...
(RTTNews) - Biopharmaceutical company Novavax, Inc. (NVAX), which advances protein-based vaccines with its novel Matrix-M adjuvant, announced on Monday that it has signed a three-year agreement with ...
Pfizer Inc. (NYSE:PFE) is one of the best inexpensive stocks to buy now. On January 20, Novavax announced a non-exclusive licensing agreement with Pfizer, granting the pharmaceutical giant access to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results